ISATORI, INC. Spending and interest coverage
- R&D / revenue · 12 months: Value 1.20%; Formula and calculation Research and development expense / revenue. Period ending 2015-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.01%; Formula and calculation Share-based compensation / revenue. Period ending 2015-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2015-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1.20% | Research and development expense / revenue. Period ending 2015-06-30. $112.80K ÷ $9.39M × 100 ≈ 1.20% |
| Stock-based compensation / revenue · 12 months | 1.01% | Share-based compensation / revenue. Period ending 2015-06-30. $95.02K ÷ $9.39M × 100 ≈ 1.01% |
| Interest coverage · 12 months | (m) | Operating income ÷ reported interest expense. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 112.80K USD | Research and Development Expense |
| Revenue | 9.39M USD | |
| Stock-based compensation | 95.02K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | Operating Income (Loss) |
| Interest expense · reported / estimated | 65.17K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2015-06-30 | $112.80K | $9.39M | $95.02K | (m) | $65.17K | 1.20% | 1.01% | (m) | Reported |
| 2015-03-31 | $111.96K | $9.82M | $65.35K | (m) | $54.71K | 1.14% | 0.67% | (m) | Reported |
| 2014-12-31 | $99.68K | $9.65M | $55.79K | (m) | $49.54K | 1.03% | 0.58% | (m) | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $84.69K | $12.31M | $237.33K | (m) | $40.71K | 0.69% | 1.93% | (m) | Reported |
| 2014-03-31 | $108.91K | $11.67M | $291.63K | (m) | $44.81K | 0.93% | 2.50% | (m) | Reported |
| 2013-12-31 | $162.30K | $10.67M | $336.30K | (m) | $32.61K | 1.52% | 3.15% | (m) | Reported |
| 2013-09-30 | $170.87K | $9.46M | $301.10K | (m) | $23.59K | 1.81% | 3.18% | (m) | Reported |
| 2013-06-30 | $112.96K | $9.16M | $127.12K | (m) | $6.04K | 1.23% | 1.39% | (m) | Reported |
| 2013-03-31 | $92.90K | (m) | $66.31K | (m) | $-144.15K | (m) | (m) | (m) | Reported |
| 2012-12-31 | $37.23K | $9.34M | $85.90K | (m) | $-205.09K | 0.40% | 0.92% | (m) | Reported |
| 2012-09-30 | $26.10K | $9.35M | $97.06K | (m) | $-283.93K | 0.28% | 1.04% | (m) | Reported |
| 2012-06-30 | $22.39K | $9.86M | $96.72K | (m) | $-325.52K | 0.23% | 0.98% | (m) | Reported |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | $-15.22K | (m) | (m) | (m) | Reported |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.